Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Granulosa cell tumor of the ovary 1

Interventions

Cetuximab 7Magnetic Resonance Spectroscopy 5Radiotherapy 4Erlotinib Hydrochloride 4Cisplatin 4Bevacizumab 4Trastuzumab 3Specimen Handling 3Radiotherapy, Conformal 3Carboplatin 3sargramostim 2ixabepilone 2Vorinostat 2Sorafenib 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Fluorouracil 2Fluorodeoxyglucose F18 2Docetaxel 2Dasatinib 2Chemotherapy, Adjuvant 2Biopsy 2trastuzumab deruxtecan 1tipifarnib 1temsirolimus 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Salivary Gland Neoplasms × luprolide acetate gel depot × Clear all
NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡